- MetaVia (MTVA, Financial) will present Phase 2a trial data on DA-1241 at EASL Congress 2025 in Amsterdam, demonstrating hepatoprotective and glucose-regulating effects.
- The presentation will be delivered by Dr. Rohit Loomba from the University of California, San Diego on May 7, 2025, at 8:30 am CET.
- The poster detailing the trial results will be accessible on MetaVia's website following the presentation.
MetaVia Inc. (MTVA), a clinical-stage biotechnology company, is set to present its Phase 2a clinical trial results of DA-1241 at the European Association for the Study of the Liver (EASL) Congress 2025, held from May 7-10 in Amsterdam, Netherlands. This late-breaking poster presentation will highlight DA-1241's hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH) from a 16-week randomized placebo-controlled trial.
The presentation, titled "DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients," will be delivered by Dr. Rohit Loomba of the University of California, San Diego.
Following the presentation, the poster will be made available in the Posters section of MetaVia's website. DA-1241, a G-Protein-Coupled Receptor 119 (GPR119) agonist, continues to show promise as a standalone or combination therapy for both MASH and type 2 diabetes, with beneficial effects on glucose and lipid metabolism, weight loss, and liver inflammation.
